Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Triple Antimalarial Combination (Imatinib-DHA-PPQ) to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites

NCT03697668 is registered in ClinicalTrials.gov with Nurex S.r.l. as lead sponsor.

NCT NCT03697668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03697668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Triple Antimalarial Combination (Imatinib-DHA-PPQ) to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites
Lead sponsor
Nurex S.r.l.
Phase
Phase 2
Overall status
Unknown status
Start date
September 17, 2017
Completion date
December 31, 2019
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plasmodium falciparum malaria (drug resistant)